spesolimab   Click here for help

GtoPdb Ligand ID: 12169

Synonyms: BI-655130 | BI655130 | spesolimab-sbzo | Spevigo®
Approved drug Immunopharmacology Ligand
spesolimab is an approved drug (FDA and EMA (2022))
Compound class: Antibody
Comment: Spesolimab (BI-655130) is a monoclonal antibody that disrupts interleukin-36 (IL-36)/IL-36 receptor signalling. Blocking this pathway is a molecular mechanism with potential to treat inflammatory diseases in skin and other epithelial tissues [2-3,5,7], since IL-36R expression is restricted to epithelial cells that are in direct contact with the environment, including those in the skin. Spesolimab (BI-655130) appears to be related to MAB92 which was reported by Boehringer Ingelheim in 2017 [6], but we have been unable to perform direct sequence matches. The heavy and light chain sequences for spesolimab (from its INN record) are claimed in Boehringer Ingelheim's patent US9023995B2 [4].
Click here for help
1. Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, Navarini AA, Zheng M, Xu J, Turki H et al.. (2021)
Trial of Spesolimab for Generalized Pustular Psoriasis.
N Engl J Med, 385 (26): 2431-2440. [PMID:34936739]
2. Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, Turki H, Hall DB, Shear M, Baum P et al.. (2019)
Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis.
N Engl J Med, 380 (10): 981-983. [PMID:30855749]
3. Baum P, Visvanathan S, Garcet S, Roy J, Schmid R, Bossert S, Lang B, Bachelez H, Bissonnette R, Thoma C et al.. (2022)
Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis.
J Allergy Clin Immunol, 149 (4): 1402-1412. [PMID:34678325]
4. Brown SE, Canada K, Chlewicki L, Howell M, Mennerich D, Woska JR. (2015)
Anti IL-36R antibodies.
Patent number: US9023995B2. Assignee: Boehringer Ingelheim International GmbH. Priority date: 16/11/2011. Publication date: 05/05/2015.
5. Ferrante M, Irving PM, Selinger CP, D'Haens G, Kuehbacher T, Seidler U, Gropper S, Haeufel T, Forgia S, Danese S et al.. (2023)
Safety and tolerability of spesolimab in patients with ulcerative colitis.
Expert Opin Drug Saf, 22 (2): 141-152. [PMID:35861588]
6. Ganesan R, Raymond EL, Mennerich D, Woska Jr JR, Caviness G, Grimaldi C, Ahlberg J, Perez R, Roberts S, Yang D et al.. (2017)
Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies.
MAbs, 9 (7): 1143-1154. [PMID:28726542]
7. Hwang J, Rick J, Hsiao J, Shi VY. (2022)
A review of IL-36: an emerging therapeutic target for inflammatory dermatoses.
J Dermatolog Treat, 33 (6): 2711-2722. [PMID:35470744]
8. Maçães CO, Lé AM, Torres T. (2022)
Generalized pustular psoriasis: the new era of treatment with IL-36 receptor inhibitors.
J Dermatolog Treat, 33 (7): 2911-2918. [PMID:35695278]